Skip to content
DataLookout
Start free
Menu

NCT06628206

Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 11 months later.

See at-risk trials from LAPIX Therapeutics Inc.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 15, 2025 to Nov 15, 2026 Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Trial sites expanded: 1 → 6 locations
    • Study completion pushed from Jan 15, 2026 to Feb 15, 2027
    • Eligibility criteria expanded, about 41 words
    • Study description revised
  2. Primary completion date: Sep 15, 2025 to Dec 15, 2025
    • Study description revised
    • Site details revised
    v5
  3. Enrollment target: 50 to 48
    • Site details revised
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 15, 2024 to Dec 15, 2024
    v3
  5. Study title revisedv2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To evaluate the safety and tolerability after multiple oral doses of LPX-TI641 in participants with RA and PsA.
Timeframe: 56 days

Secondary (2)

To evaluate the plasma pharmacokinetics after multiple oral doses of LPX TI641 in participants with RA and PsA.
To evaluate the plasma pharmacokinetics after multiple oral doses of LPX TI641 in participants with RA and PsA

Arms and interventions

Rheumatoid arthritisExperimental

LPX-TI641 or Placebo

Psoriatic ArthritisExperimental

LPX-TI641 or Placebo

Drugs: LPX-TI641, Placebo

Sites

6 sites in 2 countries

United States 5, Jordan 1